This course has expired. You can still review the content but course credit is no longer available.
Introduction and Overview: Where We’ve Come in Gene Therapy - Presented By Allen C. Ho, MD
Ocular Gene Therapy Delivery - Presented By Robert Avery, MD
Gene Therapy for Wet AMD: Current Clinical Trials - Presented By Jeffrey S. Heier, MD
Changing Retinal Landscape and Implications for Future Therapies - Presented By Pravin U. Dugel, MD
Closing Comments and CME Posttest - Presented By Allen C. Ho, MD
This activity is supported from an educational grant from REGENXBIO.
Allen C. Ho, MD
Wills Eye Hospital
Pravin U. Dugel, MD
Retinal Consultants of Arizona
Robert Avery, MD
California Retina Consultants
Jeffrey S. Heier, MD
Ophthalmic Consultants of Boston
Pravin U. Dugel, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board Member: Abbott/AMO, Acucela, Aerie Pharmaceuticals, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArticDX, Avalanche, Bausch + Lomb, Boehringer lngelheim, ByeOnics, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Clearside Biomedical, CDR-Life Inc., Digisight, Dose Medical, Genentech, Graybug Vision, lrenix, Kodiak Sciences, Lutronic, Lux Bioscience, Macusight, NeoVista, Neurotech, Novartis, Oculis, Ophthotech, Omeros, Opthea, Optovue, ORA, Orbis International, Panoptica, Pentavision, pSivida Corporation, QLT, Inc., Regeneron, Roche, Santen, SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth, Biotherapeutics, Thrombogenetics, Topcon, and TrueVision. Stock/Shareholder: Aerpio, Alimera, Annidis, ArctixDx, Clearside Biomedical, Digisight, lrenix, Ophthotech and PanOptic.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or REGENXBIO.